论文部分内容阅读
目的观察缬沙坦对2型糖尿病(DM)患者的尿微量白蛋白、肾功能的影响。方法 70例2型糖尿病合并尿微量白蛋白患者分为缬沙坦治疗组(治疗组,n=35)和依那普利组(对照组,n=35),疗程共12周。分别比较治疗前后两组患者的收缩压(SBP)、舒张压(DBP)、尿微量白蛋白(UAER)、血肌酐(Scr)、血尿素氮(BUN)、空腹血糖(FBG)、空腹胰岛素(FBI)水平及药物不良反应情况。结果治疗组与对照组降低尿微量白蛋白总有效率分别为90.2%和50.6%,两组治疗后FBG、UAER、Scr、BUN等水平较治疗前均下降,具有统计学意义(P<0.05),且治疗组优于对照组。结论缬沙坦治疗2型糖尿病合并尿微量白蛋白更加合理有效,而且无明显不良反应。
Objective To observe the effects of valsartan on urinary albumin and renal function in type 2 diabetic patients. Methods Seventy patients with type 2 diabetes mellitus and microalbuminuria were divided into valsartan treatment group (n = 35) and enalapril control group (n = 35) for 12 weeks. The SBP, DBP, UAER, Scr, BUN, FBG, fasting insulin (FBG) and fasting blood glucose FBI) levels and adverse drug reactions. Results The total effective rate of reducing microalbuminuria in the treatment group and control group was 90.2% and 50.6% respectively. The levels of FBG, UAER, Scr and BUN decreased after treatment in both groups, with statistical significance (P <0.05) , And the treatment group is better than the control group. Conclusions Valsartan is more reasonable and effective in the treatment of type 2 diabetes mellitus with urinary albumin, and no obvious adverse reactions.